BDBM195904 US9206188, 145::US9834551, Example 145

SMILES CN(C)C\C=C\C(=O)Nc1cccc(c1)-c1cnc2[nH]cc(-c3cccc(C)c3F)c2c1

InChI Key InChIKey=PRIQLBRXOCMBJB-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 195904   

TargetTyrosine-protein kinase JAK3(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 5nMAssay Description:1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Ja...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2016
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 72.4nMAssay Description:1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Ja...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2016
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 100nMAssay Description:ITK and JAK3 Kinase assay procedures:Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 100nMAssay Description:ITK and JAK3 Kinase assay procedures:Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 154nMAssay Description:1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Ja...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2016
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 7.56E+3nMAssay Description:1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Ja...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2016
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM195904(US9206188, 145 | US9834551, Example 145)
Affinity DataIC50: 1.00E+5nMAssay Description:1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Ja...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2016
Entry Details
US Patent